Dawn Odom

886 total citations
46 papers, 681 citations indexed

About

Dawn Odom is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Psychiatry and Mental health. According to data from OpenAlex, Dawn Odom has authored 46 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Psychiatry and Mental health. Recurrent topics in Dawn Odom's work include Colorectal Cancer Treatments and Studies (9 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Dawn Odom is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Dawn Odom collaborates with scholars based in United States, Germany and Switzerland. Dawn Odom's co-authors include Catherine B. Johannes, Raymond C. Rosen, Patrícia A. Russo, Brigitta U. Monz, Jan L. Shifren, James A. Kaye, Anita H. Clayton, Bintu Sherif, Emmanuel Aris and Cosmina Hogea and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and Annals of Oncology.

In The Last Decade

Dawn Odom

45 papers receiving 655 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dawn Odom United States 14 250 140 111 100 84 46 681
Gianluigi Califano Italy 19 109 0.4× 154 1.1× 230 2.1× 71 0.7× 44 0.5× 111 1.0k
Paolo Casadio Italy 25 69 0.3× 115 0.8× 115 1.0× 41 0.4× 54 0.6× 130 2.1k
Yali Fu China 9 435 1.7× 361 2.6× 339 3.1× 181 1.8× 147 1.8× 15 1.0k
Lynne P. Taylor United States 18 60 0.2× 137 1.0× 149 1.3× 69 0.7× 34 0.4× 48 760
H. Jeffrey Wilkins United States 10 146 0.6× 103 0.7× 391 3.5× 60 0.6× 89 1.1× 21 1.3k
Jimmy Hwang United States 16 36 0.1× 272 1.9× 111 1.0× 56 0.6× 118 1.4× 38 882
E.B.L. van Dorst Netherlands 12 73 0.3× 282 2.0× 36 0.3× 17 0.2× 98 1.2× 24 1.0k
Karin Bergmark Sweden 21 162 0.6× 880 6.3× 207 1.9× 82 0.8× 83 1.0× 52 1.9k
Geolani W. Dy United States 18 100 0.4× 77 0.6× 137 1.2× 197 2.0× 12 0.1× 61 1.3k
Mine Özkan Türkiye 12 45 0.2× 165 1.2× 46 0.4× 68 0.7× 52 0.6× 41 651

Countries citing papers authored by Dawn Odom

Since Specialization
Citations

This map shows the geographic impact of Dawn Odom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Odom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Odom more than expected).

Fields of papers citing papers by Dawn Odom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Odom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Odom. The network helps show where Dawn Odom may publish in the future.

Co-authorship network of co-authors of Dawn Odom

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Odom. A scholar is included among the top collaborators of Dawn Odom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Odom. Dawn Odom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rousculp, Matthew D., Kelly Hollis, Ryan Ziemiecki, et al.. (2024). Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines. Vaccines. 12(7). 802–802. 2 indexed citations
2.
Rousculp, Matthew D., Kelly Hollis, Ryan Ziemiecki, et al.. (2024). Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study. Vaccines. 12(1). 83–83. 4 indexed citations
3.
Samuelson, Thomas W., Inder Paul Singh, Blake K. Williamson, et al.. (2021). Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI From the iStent inject® Pivotal Trial. American Journal of Ophthalmology. 229. 220–229. 43 indexed citations
4.
Hofheinz, Ralf‐Dieter, et al.. (2021). Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. Cancer Management and Research. Volume 13. 5523–5533. 9 indexed citations
5.
Richardson, David B., Lin Zhan, Reshma Mahtani, et al.. (2021). A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Research and Treatment. 187(1). 113–124. 9 indexed citations
6.
Samuelson, Thomas W., Inder Paul Singh, L. Jay Katz, et al.. (2019). PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS. Value in Health. 22. S890–S890. 1 indexed citations
7.
Hofheinz, Ralf‐Dieter, et al.. (2019). Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types. Annals of Oncology. 30. iv37–iv37. 1 indexed citations
8.
Odom, Dawn, et al.. (2017). A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma. Journal of Skin Cancer. 2017. 1–7. 26 indexed citations
9.
Chirila, Costel, Debanjali Mitra, Ann Colosia, et al.. (2016). Efficacy of Palbociclib Combinations Versus Endocrine Therapies in Advanced/ Metastatic Breast Cancer: Network Meta-Analysis. Value in Health. 19(7). A710–A710. 3 indexed citations
10.
Odom, Dawn, et al.. (2016). A Matching Adjusted Indirect Comparison Of Sonidegib And Vismodegib In Advanced Basal Cell Carcinoma. Value in Health. 19(3). A122–A122. 2 indexed citations
11.
Mladsi, Deirdre, et al.. (2016). Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac. Clinical Therapeutics. 38(11). 2418–2429.
12.
Odom, Dawn, et al.. (2015). Methods To Assess The Association Of Patient-Reported Outcomes And Clinical Endpoints. Value in Health. 18(3). A6–A6. 2 indexed citations
13.
Odom, Dawn, et al.. (2014). Practical issues when conducting network meta-analyses with a limited number of studies. Value in Health. 17(3). A205–A205. 1 indexed citations
14.
Odom, Dawn, Deirdre Mladsi, Kenneth G. Saag, et al.. (2014). Relationship Between Diclofenac Dose and Risk of Gastrointestinal and Cardiovascular Events: Meta-Regression Based on Two Systematic Literature Reviews. Clinical Therapeutics. 36(6). 906–917. 27 indexed citations
15.
Odom, Dawn, Anita J. Brogan, Sandra E. Talbird, & Brad Schenkel. (2013). A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Value in Health. 16(3). A112–A112. 3 indexed citations
16.
Chirila, Costel, Dawn Odom, Giovanna Devercelli, et al.. (2011). Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. International Journal of Colorectal Disease. 27(5). 623–634. 25 indexed citations
17.
Rosen, Raymond C., Jan L. Shifren, Brigitta U. Monz, et al.. (2009). Correlates of Sexually Related Personal Distress in Women with Low Sexual Desire. The Journal of Sexual Medicine. 6(6). 1549–1560. 163 indexed citations
18.
Johannes, Catherine B., Anita H. Clayton, Dawn Odom, et al.. (2009). Distressing Sexual Problems in United States Women Revisited. The Journal of Clinical Psychiatry. 70(12). 1698–1706. 75 indexed citations
19.
20.
Caspar, Rachel, et al.. (2002). Nonresponse in the 1999 NHSDA. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gianluigi Califano Breakdown of academic impact, for papers by Paolo Casadio Breakdown of academic impact, for papers by Yali Fu Breakdown of academic impact, for papers by Lynne P. Taylor Breakdown of academic impact, for papers by H. Jeffrey Wilkins Breakdown of academic impact, for papers by Jimmy Hwang Breakdown of academic impact, for papers by E.B.L. van Dorst Breakdown of academic impact, for papers by Karin Bergmark Breakdown of academic impact, for papers by Geolani W. Dy Breakdown of academic impact, for papers by Mine Özkan
Rankless by CCL
2026